TP53 and neoplasm: VSV achieves its oncolytic effects by activating multiple caspase-dependent apoptotic cascades, including high efficacy against tumor cells carrying activated oncogenes (e.g., Ras and Myc) or inactivated tumor suppressor pathways (e.g., p53) (10).